$TNYA News

Tenaya Therapeutics Reports New Interim Safety And Efficacy Data From MyPEAK-1 Phase 1b/2 Clinical Trial Of TN-201

Tenaya Therapeutics To Report New Interim Data From Cohort 1 And 2 Of Ongoing MyPEAK-1 Phase 1b/2 Trial Of TN-201 Gene Therapy For Adults With MYBPC3-Associated Hypertrophic Cardiomyopathy On June 3

Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC - Slideshow

Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVC Transcript

Tenaya Therapeutics, Inc. (TNYA) Presents at Heart Failure 2026 - Slideshow

Tenaya Therapeutics' Gene Therapy Data Highlights Early Heart Rhythm Improvements

Tenaya Therapeutics Q1 EPS $(0.09) Misses $(0.06) Estimate, Sales $25.000M Beat $10.000M Estimate

Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026

Tenaya Therapeutics Announces Acceptance Of Multiple Abstracts For Presentation At ASGCT Annual Meeting; To Feature New Clinical Data From Both Dose Cohorts Of RIDGE-1 Phase 1b/2 Trial Of TN-401 As Late-Breaking Oral Presentation

When Will Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Become Profitable?

Tenaya Therapeutics Q4 EPS $(0.12) Beats $(0.13) Estimate

Tenaya Therapeutics Presents Prelinical Data Of TN-301 At Muscular Dystrophy Association's Clinical & Scientific Conference 2026

Tenaya Therapeutics shares are trading higher after the company announced a research collaboration agreement with Alnylam Pharmaceuticals to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.

Tenaya Therapeutics shares are trading higher after the company announced a research collaboration agreement with Alnylam Pharmaceuticals to discover novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.

Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Tenaya Therapeutics Issues Update On Clinical Development Programs And Outlines Strategic Priorities For 2026; Aims To Build On Positive 2025 Interim TN-201 Results In H1 2026

Tenaya Therapeutics (TNYA) Is Down 39.7% After Cardiac Gene Therapy Milestones And $60M Fundraise - What's Changed

Tenaya Stock Plunges After $60 Million Equity Offering

HC Wainwright & Co. Maintains Buy on Tenaya Therapeutics, Lowers Price Target to $3

Tenaya Therapeutics shares are trading lower after the company announced the pricing of a $60 million public offering of 50 million units at $1.20 per unit.